Paclitaxel-hyaluronan hydrosoluble bioconjugate: mechanism of action in human bladder cancer cell lines (Q39395641)

11 September 2017

Paclitaxel-hyaluronan hydrosoluble bioconjugate: mechanism of action in human bladder cancer cell lines (English)

1 reference

11 September 2017

1 reference

Isabella Monia Montagner

1

1 reference

11 September 2017

Alessandra Banzato

2

1 reference

11 September 2017

Gaia Zuccolotto

3

1 reference

11 September 2017

Davide Renier

4

1 reference

11 September 2017

Monica Campisi

5

1 reference

11 September 2017

Pierfrancesco Bassi

6

1 reference

11 September 2017

Paola Zanovello

7

1 reference

11 September 2017

Antonio Rosato

8

1 reference

11 September 2017

16 February 2012

1 reference

11 September 2017

1 reference

11 September 2017

31

1 reference

11 September 2017

7

1 reference

11 September 2017

1261-1269

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.01.005

11 September 2017

1 reference

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.01.005

Bladder cancer in 2010: how far have we come?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.01.005

Bacillus Calmette-Guérin treatment of non-muscle invasive bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.01.005

Individualized pharmacotherapy with paclitaxel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.01.005

Microtubules as a target for anticancer drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.01.005

Pharmacologic effects of paclitaxel in human bladder tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.01.005

Intravesical therapy for superficial cancer: need for more options

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.01.005

Hypersensitivity reactions from taxol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.01.005

Paclitaxel incorporated in hydrophobically derivatized hyperbranched polyglycerols for intravesical bladder cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.01.005

The uptake of paclitaxel and docetaxel into ex vivo porcine bladder tissue from polymeric micelle formulations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.01.005

HYTAD1-p20: a new paclitaxel-hyaluronic acid hydrosoluble bioconjugate for treatment of superficial bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.01.005

Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.01.005

Target specific and long-acting delivery of protein, peptide, and nucleotide therapeutics using hyaluronic acid derivatives.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.01.005

RHAMM, a receptor for hyaluronan-mediated motility, compensates for CD44 in inflamed CD44-knockout mice: a different interpretation of redundancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.01.005

CD44 in cancer progression: adhesion, migration and growth regulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.01.005

Hyaluronan-CD44 interactions as potential targets for cancer therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.01.005

Cell-surface and mitotic-spindle RHAMM: moonlighting or dual oncogenic functions?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.01.005

Expression of CD44 standard and variant-v6 proteins in transitional cell bladder tumours and their relation to prognosis during a long-term follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.01.005

CD44-dependent intracellular and extracellular catabolism of hyaluronic acid by hyaluronidase-1 and -2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.01.005

A paclitaxel-hyaluronan bioconjugate targeting ovarian cancer affords a potent in vivo therapeutic activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.01.005

Formation and antitumor activity of PNU-159682, a major metabolite of nemorubicin in human liver microsomes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.01.005

Microtubule-targeted anticancer agents and apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.01.005

Unimolecular micelles based on hydrophobically derivatized hyperbranched polyglycerols: ligand binding properties

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.01.005

Polyester-based micelles and nanoparticles for the parenteral delivery of taxanes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.01.005

Hyaluronic acid coated poly(butyl cyanoacrylate) nanoparticles as anticancer drug carriers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.01.005

Paclitaxel-containing nano-engineered polymeric capsules towards cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.01.005

Paclitaxel-hyaluronic acid for intravesical therapy of bacillus Calmette-Guérin refractory carcinoma in situ of the bladder: results of a phase I study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.01.005

A hyaluronic acid-taxol antitumor bioconjugate targeted to cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.01.005

Immunological functions of hyaluronan and its receptors in the lymphatics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.01.005

The in vitro rabbit whole bladder as a model to investigate the urothelial transport of anticancer agentsThe ONCOFID-P® paradigm

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.01.005

Hyaluronan metabolism in remodeling extracellular matrix: probes for imaging and therapy of breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2012.01.005

10.1016/J.UROLONC.2012.01.005

7 January 2021

Identifiers

DOI

1 reference

11 September 2017

1 reference